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Background: Diabetes is undoubtedly one of the most challenging health problems in 21st century. Understanding
the pathogenesis and preventing long term complications have been major goals of research in diabetes mellitus
(DM). Research in the past few years has linked oxidative stress and inflammation to beta cell dysfunction. Aim of
this study is to evaluate serum gamma-glutamyl transferase (GGT) activity (marker of oxidative stress) and high
sensitivity C reactive protein (hsCRP) level (an inflammatory marker) in type 2 DM subjects with good and poor
glycemic control. Further, we investigated correlation between serum GGT and hsCRP level with glycemic control
(FBS, PP2BS, HbA1c) in subjects.
Methods: A cross sectional study consists of 150 patients out of them 50 patients having type 2 DM with good
control (Group II), 50 patients with type 2 DM with poor control (Group III) and 50 normal healthy control (Group I)
were selected. Serum GGT, serum hsCRP, FBS, PP2BS, HbA1c, and other biochemical investigations include serum
liver enzymes and lipids were measured.
Results: Mean serum GGT and hsCRP concentration were statistically significantly higher in group III patients
compared to group I and group II subjects as well as increased in group II compared to group I (p < 0.001). Further
significant positive correlation was observed between GGT and hsCRP concentration as well as both with HbA1c,
FBS, and PP2BS.
Conclusions: Oxidative stress and inflammation appears to be a key component and also associated with poor
glycemic control and further pathogenesis of diabetes and its complications. All our finding suggesting a link
between oxidative stress, inflammation and glycemic control in patient with type 2 diabetes mellitus.Background
Diabetes mellitus (DM) comprises a group of common
metabolic disorders that share common phenotype of
hyperglycemia [1]. Hyperglycemia not only defines the
disease but is the cause of its most characteristic symp-
toms and long-term complications. Understanding the
pathogenesis and preventing long-term complications
have been major goals of research in diabetes mellitus.
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distribution, and reproduction in any mediumhealth problems in 21st century [2]. Research in the past
few years has linked oxidative stress and inflammation
to β-cell dysfunction resulting from chronic exposure to
hyperglycemia. A growing body of data reinforces the con-
cept that inflammation plays an important role in the
pathogenesis of type 2 DM and links DM with concomi-
tant conditions with inflammatory components [3].
Gamma-glutamyl transferase (GGT, E.C.2.3.2.2) is a
cell-surface protein contributing to the extracellular ca-
tabolism of glutathione (GSH). The enzyme is produced
in many tissues, but most GGT in serum is derived from
the liver [4]. GGT has a pivotal role in the maintenance
of intracellular antioxidant defences through its medi-
ation of extracellular glutathione (GSH) transport intoentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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a number of pathological conditions, such as inflamma-
tion, carcinogenesis, aging, atherosclerosis, and reperfu-
sion injury [6]. Oxidative stress can also play a role in
the cause and pathophysiology of diabetes. Most studies
focus on the role of oxidative stress in developing car-
diovascular complications in diabetic patients, [7]. More-
over, elevated GGT is strongly associated with obesity
and excess deposition of fat in the liver, termed non-
alcoholic fatty liver disease, which is thought to cause
hepatic insulin resistance and to contribute to the devel-
opment of systemic insulin resistance and hyperinsuline-
mia [8]. Thus, GGT might reflect metabolic alterations
and could serve as a marker of the insulin resistance
syndrome. Other studies suggested that GGT plays an
important role in antioxidant systems [5,9].
High sensitivity C-reactive protein (hsCRP) is a C-
reactive protein measured by a highly sensitive assay.
CRP represents the classical acute-phase protein pro-
duced in the liver in response to inflammatory stimuli,
and plasma levels of hsCRP provide a sensitive marker
of increased inflammatory activity in the arterial wall
[10]. Chronic, systemic subclinical inflammation has also
been identified as a driving force for insulin resistance,
metabolic syndrome, and type 2 DM. Some related
metabolic disorders include abdominal adiposity, hyper-
tension, endothelial dysfunction, and glucose intoler-
ance, which often occur in a cluster. Insulin resistance
correlates closely with the risk of cardiovascular diseases
(CVD), explaining some of the excess morbidity and
mortality in type 2 DM patients [11,12].
Because the development of complications is linked to
the accumulation of glycation adducts in tissue proteins.
The core of the issue is glycemic control. Optimal moni-
toring of glycemic control involves plasma glucose mea-
surements (fasting and postprandial blood sugar) and
measurement of glycated hemoglobin (HbA1c). These
measurements are complementary: the patient’s glucose
measurements provide a picture of short-term glycemic
control, whereas HbA1c reflects average glycemic con-
trol over the previous 3 months [1].
Since, oxidative stress and inflammation appears to be
a key component of many reactions associated with poor
glycemic control and further pathogenesis of diabetes
and its complications; we found it interesting to study
serum GGT activity (marker of oxidative stress) and
hsCRP level (an inflammatory marker) in diabetic sub-
jects. Further, we investigated correlation between serum
GGT and hsCRP with glycemic control in subjects.
Methods
Study design and subjects
This study was a hospital based cross sectional study
conducted at shree sayajirao general hospital and medicalcollege, Vadodara (India) between May 2009 to June 2010.
A cross sectional study consists of 150 subjects out of
them 50 patients having type 2 DM with good glycemic
control (Group II), 50 patients with type 2 DM with poor
glycemic control (Group III) and 50 normal healthy
control (Group I) were selected. Subjects were recruited




The subjects selected for study were grouped as follows:
Group I – Control group (n=50) This group consisted
of age and sex matched healthy subjects. They were free
from any ailment which could affect the parameters
under study. They were not on any medication. They
were taken from general population.
Group II – Type 2 DM patients with good glycemic
control (n=50) This group consisted of patients with
type 2 DM with duration less than 8 years, HbA1c level
less than 7%. They were on life style modifications and
oral hypoglycemic drugs and free from clinical evidence
of any complication of diabetes mellitus.
Group III – Type 2 DM patients with poor glycemic
control (n=50) This group consisted of patients with
type 2 DM with duration more than 8 years, HbA1c
level more than 7%. They were on life style modifica-
tions, oral hypoglycemic drugs, insulin or combination
of all three and associated with one or more micro-
vascular or macrovascular complication of diabetes mel-
litus for e.g. diabetic retinopathy, heart disease, diabetic
neuropathy.
Exclusion criteria
The patients with type 1 diabetes mellitus, high (>30 g/d)
alcohol consumption, with known liver or gastrointestinal
diseases, with liver enzyme concentrations higher than
three times the upper limit, on corticosteroids, methotrex-
ate, amiodarone, tamoxifen or other hepatotoxic drugs,
any chronic infection like tuberculosis, sarcoidosis etc.,,
hemolytic anaemia, hemoglobin variants were excluded
from this study.
Ethical considerations
The objectives of study were explained to all eligible
subjects for this study. Informed written consent of
all subjects included in the study was obtained for
involvement in study groups and for venipuncture.
Emphasis was given that participation in this study
was voluntary.
Table 1 Values of Serum GGT and hsCRP concentration
between study groups
Study Groups GGT (U/L) hsCRP (mg/L)
Group I 24.78 ± 5.8 1.4 ± 0.4
Group II 30.06 ± 7.02 2.50 ± 0.78
t value 2.93 6.8
p values < 0.05 < 0.001
Group II 30.06 ± 7.02 2.50 ± 0.78
Group III 39.5 ± 12.68 3.84 ± 1.09
t value 5.23 8.28
p values < 0.001 < 0.001
Group I 24.78 ± 5.8 1.4 ± 0.4
Group III 39.5 ± 12.68 3.84 ± 1.09
t value 8.16 15.09
p values < 0.001 < 0.001
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A questionnaire was specifically designed to obtain in-
formation which helps to select individuals according to
the selection criteria of the study. The questions also
focused on baseline information on socio-demographic
variables (age, sex) and background characteristics of
diabetes (duration and type of diabetes mellitus, mode of
anti-diabetic therapy, any complication) during a stan-
dardized interview. In addition, all participants under-
went an extensive standardized medical examination
including the collection of blood sample.
Blood sample collection
A 5 ml of venous blood was drawn from each volunteer
using a disposable vacutainer system in fasting condition
(Plain, EDTA and Fluoride). Post prandial (2 hour) sam-
ple collected in fluoride vacutainer for PP2BS estimation.
Serum or plasma separated within half an hour and
stored at 2-8°C temperature till analysis was done.
Analysis of sample
Fasting and post prandial (2 hour) blood sugar (FBS &
PP2BS) estimated by glucose oxidase-peroxidase (GOD-
POD) enzymatic end point method (Kit: Quantitative de-
termination blood sugar by glucose oxidase peroxidase
method mfg by Spinreact). Glycated hemoglobin (HbA1c)
concentration was measured by immuno turbidimetric
method (Kit: Quantitative determination of glycated
hemoglobin (HbA1c) in human blood by latex turbi-
dimetry mfg by Spinreact). Serum GGT activity was de-
termined by carboxy substrate kinetic method. (Kit:
Quantitative determination of GGT by carboxy substrate
method mfg by Coral Crest biosystems). Serum hsCRP
level is measured by immuno turbidimetric method (Kit:
Quantitative determination of hsCRP in human blood by
latex turbidimetry assay mfg by Spinreact). All other bio-
chemical investigation includes serum liver enzymes,
lipids, and other biochemical blood measurements were
determined using standard laboratory procedures on fully
automatic analyzer I.S.E. srl MIURA. Hemogram and
urine examination were done in pathology laboratory.
Fundoscopy and electrocardiogram were done in respect-
ive department.
Statistical analysis
The data collected during the current study were re-
corded and analysed statistically to determine the signifi-
cance of different parameters by using GraphPad InStat
statistical software. Results are expressed as mean ± SD.
The values between groups are compared using one way
ANOVA test. P value of < 0.05 was considered statisti-
cally significant. Pearson linear correlation was used to
study correlation between parameters.Results
Our study shows mean serum GGT concentration in
group III was significantly higher compared to control
(group I) and group II cases (p values < 0.001). Also
serum GGT concentration in group II was significantly
higher compared to group I (p values < 0.05). Further
mean hsCRP levels in group III and group II were sig-
nificantly higher compared to group I (p values < 0.001).
Also hsCRP level in group III was higher than group II
(p values < 0.001) (Table 1). We have found a statistically
significant positive linear relationship between serum
GGT and serum hsCRP concentration and with glycemic
control (HbA1c, FBS, and PP2BS). Also a significant
positive association was observed between serum hsCRP
level with glycemic control (HbA1c, FBS, and PP2BS)
(Table 2; Figures 1, 2 and 3).
Baseline characteristics of control and subjects as well
other biochemical parameter are given in Table 3. Base-
line characteristics like age, sex, blood pressure, BMI
were not differing between groups. We found signifi-
cantly increased serum alanine transaminase (ALT) and
aspartate transaminase (AST) concentration in group III
compared to group I and group II (p values < 0.001).
But serum alkaline phosphatase (ALP) concentration is
not increased between groups (p value is 0.62 which
considered not significant).
Discussion
Our study shows statistical significantly increased con-
centration of GGT and hsCRP in serum in patient with
type 2 DM with poor glycemic control compared to
healthy persons as well as subjects having type 2 DM
with good glycemic control. Also we found a significant
positive linear relationship between GGT and hsCRP
concentration as well as both with HbA1C, FBS, and
PP2BS. These findings suggest a link between oxidative
Table 2 Pearson’s correlation analysis between serum





Serum GGT with hsCRP 0.80 < 0.0001
Serum GGT with HbA1c 0.79 < 0.0001
Serum GGT with FBS 0.54 < 0.0001
Serum GGT with PP2BS 0.53 < 0.0001
Serum hsCRP with HbA1c 0.78 < 0.0001
Serum hsCRP with FBS 0.56 < 0.0001
Serum hsCRP with PP2BS 0.63 < 0.0001
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tion), inflammation (raised hsCRP concentration) and
glycemic control in patients with type 2 DM and related
complications. Also at levels of GGT and hsCRP consid-
ered well within the normal range, there was a substan-
tial and significant increased concentration in patients
with type 2 DM with good glycemic control compared
to healthy subjects. This suggests a role of oxidative
stress and chronic low grade inflammation in pathogen-
esis of type 2 diabetes patients.
Several possible mechanisms which explain increased
serum GGT activity and hsCRP level in patients with
type 2 DM with good and poor control and its correl-





























Figure 1 Showing correlation between serum GGT and hsCRP concenElevation of serum GGT could be the expression of
an excess deposition of fat in the liver, termed non-
alcoholic fatty liver disease. Fatty liver is thought to
cause hepatic insulin resistance and to contribute to the
development of systemic insulin resistance and hyperin-
sulinemia. Thus, GGT could serve as a marker of the
insulin resistance syndrome in the pathogenesis of dia-
betes [8,13].
There is now growing evidence to suggest that GGT is
not only a marker of fatty liver but also a marker of oxi-
dative stress. Experimental studies have reported that
GGT has a central role in the maintenance of intracellu-
lar antioxidant defences through its mediation of extra-
cellular glutathione transport into most types of cells [5].
It is an ectoenzyme normally present at the outer side of
the cell membrane that has the primary function of
maintaining intracellular concentrations of glutathione
(GSH), a critical antioxidant defence for the cell. In-
creases in GGT activity can be a response to oxidative
stress, facilitating increased transport of GSH precursors
into cells. In addition, GGT is leaked into the serum
possibly as a result of normal cell turnover and cellular
stresses. Several mechanisms for GGT leakage are pos-
sible and include increases in oxidative stress, proteoly-
sis, glycosylation, GGT synthesis and endothelial cell
damage [14]. Thus, increased serum concentrations of
GGT could identify people with a low but persistent
























Serum GGT concentration (U/L)
Figure 2 Showing correlation between serum GGT and HbA1c concentration in patients.
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underlying diabetes and diabetic complications. In recent
years, much attention has been focused on the role of
oxidative stress, and it has been reported that oxidative























Figure 3 Showing correlation between serum hsCRP and HbA1c concpathogenesis of secondary diabetic complications. Implica-
tion of oxidative stress in the pathogenesis of diabetes is
suggested, not only by oxygen free-radical generation, but
also due to nonenzymatic protein glycosylation, auto-
oxidation of glucose, impaired glutathione metabolism,4 5 6 7
entraiton (mg/L)
entration in patients.
Table 3 Comparison of baseline characteristics and other biochemical parameters between study groups
Group I Group II Group III
Number of subjects 50 50 50
Sex (M/F) % 53/47 51/49 55/45
Age (In Years) 56 55 59
Duration of diabetes (In years) - 5.11 12.28
Height (cm) 155.94 ± 8.029 154.3 ± 4.22 157.4 ± 4.41
Weight (kg) 57.96 ± 4.535 63.6 ± 5.67 66.6 ± 5.78
BMI 24.16 ± 5.1359 26.77 ± 2.877 26.86 ± 2.48
Serum GGT concentration (U/L) 24.78 ± 5.8 30.06 ± 7.02 39.5 ± 12.68
Serum hsCRP concentration (mg/L) 1.4 ± 0.4 2.50 ± 0.78 3.84 ± 1.09
HbA1c (%) 5.48 ± 0.48 6.36 ± 0.43 8.19 ± 1.03
FBS (mg/dl) 90.68 ± 14.58 125.64 ± 27.08 194.26 ± 56.6
PP2BS (mg/dl) 113.18 ± 14.18 158.54 ± 23.85 274.08 ± 63.00
Total Cholesterol (mg/dl) 147.7 ± 25.9 193.32 ± 51.5 201.76 ± 58.17
Triglycerides total (mg/dl) 103.36 ± 23.2 130.98 ± 32.0 140.56 ± 65.2
ALT (U/L) 18.52 ± 6.0 21.46 ± 20.7 27.8 ± 5.66
AST (U/L) 19.12 ± 5.3 21.3 ± 5.6 25.9 ± 6.1
ALP (U/L) 140.36 ± 34.6 147.4 ± 30.2 144.2 ± 43.1
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tion and decreased ascorbic acid levels. In addition to
GSH, there are other defence mechanisms against free rad-
icals like enzymes superoxide dismutase (SOD), glutathi-
one peroxidase (GPx) and catalase (CAT) whose activities
contribute to eliminate superoxide, hydrogen peroxide and
hydroxyl radicals [15]. Raised GGT concentrations could
be a marker of oxidative stress, which might also play a
role in the cause and development of diabetes and its com-
plications [5,9].
Various studies suggested that elevated serum GGT
could be the expression of subclinical inflammation
which also contributes to the development of type 2 DM
[16,17]. As serum GGT is highly associated with WBC
count and some features of low-graded inflammation, so
elevated GGT could be the expression of subclinical
inflammation or an insulin-resistant state, which would
represent the underlying mechanism [17,18]. It is there-
fore suggested that measurements of other inflammatory
markers including C-reactive protein by a validated
high-sensitivity assay be added in an attempt to substan-
tiate this hypothesis.
There are various studies which support our results.
R Sharma et al. shows rise in levels of hsCRP and GGT
in diabetic subjects and their significant association
which might be a result of inflammation and oxidative
stress in diabetes mellitus [19]. Dilshad Ahmed Khan
et al. studied diabetic patients had significantly elevated
median of HbA1c, hsCRP, total cholesterol, nitrate and
GGT as compared to controls. HbA1c showed a positive
correlation with hsCRP, total cholesterol, nitrate and GGT.Oxidative stress and inflammatory markers should be
used in addition to HbA1c for assessment of increased
cardiac risk in uncontrolled diabetic patients because of
accelerated atherosclerosis due to free radical injury
[20]. Sarinnapakorn V et al. found that hsCRP levels
correlated with HbA1c levels. Mean HbA1c levels were sig-
nificantly higher in patients who had hsCRP levels of 1
mg/L or more. Other factors such as age, blood pressure,
BMI, LDL cholesterol, serum creatinine were not corre-
lated with hsCRP level [21]. Also Bahceci M et al. compare
serum hsCRP levels in type 2 diabetic men without coron-
ary heart diseases (CHD), non-diabetic CHD patients and
type 2 DM patients with CHD and shows type 2 DM men
without CHD had similar CRP levels with non-diabetic
CHD patients, whereas CRP levels of type 2 DM men with
CHD were higher than non-diabetic men with CHD. Be-
cause of a positive correlation between serum hsCRP and
HbA1c, fasting insulin and HOMA-IR, inflammation, in-
sulin resistance and hyperglycemia jointly contribute to
the cardiovascular risk in type 2 DM men [22].
Other lines of evidence support a relationship between
elevated serum GGT and poor glycemic control and
metabolic syndrome are also found. Higher GGT levels
are accompanied by more insulin resistance and greater
risk for developing type 2 DM and poor glycemic con-
trol [23-27]. The strong association of serum GGT activ-
ity with some diabetes related metabolic disorders, such
as atherogenic dyslipidemia and poor glycemic control,
may be explained by underlying, not mutually exclusive,
biological mechanisms such as fatty liver, insulin re-
sistance, and enhanced oxidative stress [23,28-32]. It is
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tions plays a direct role in the pathogenesis of atherogenic
dyslipidemia and poor glycemic control, independently of
the presence of fatty liver, possibly through the induction
of chronic inflammation and insulin resistance [33]. Sup-
porting a role of serum GGT in the inflammation and oxi-
dative stress, serum GGT level predicted future levels of
inflammation and oxidative stress markers, such as fi-
brinogen, uric acid, CRP, and F2-isoprostanes, in a dose–
response manner [34]. Several studies demonstrate that
hsCRP remained a significant predictor of diabetes risk
even after adjusting with body mass index, family history
of diabetes mellitus, smoking and other factors.
In general, serum GGT concentration is closely related
with other enzymes more specific to the liver, serum
ALT or AST concentration, so we did parallel analyses
with ALT and AST to further explore the possible role
of liver damage in the association of GGT with diabetes.
Within their normal ranges, ALT and AST showed sig-
nificant increase in type 2 diabetes patients with poor
control (p value <0.001). Moreover, markers of hepatic
fat content, such as serum GGT activity and other liver
enzymes, have been shown in large prospective studies
to predict the incidence of type 2 diabetes, insulin resist-
ance, and cardiovascular disease independently of obes-
ity [23,28,35,36].
Our results also suggest that liver enzymes are closely
associated with the risk of metabolic syndrome and type
2 diabetes and that among these enzymes serum GGT is
the most powerful risk indicator for developing the
metabolic syndrome and type 2 diabetes. Another pos-
sible pathophysiological mechanism is that elevated liver
enzymes may reflect inflammation, which impairs insulin
signalling both in the liver and systemically [27,37,38].
In this population, mean WBC count increased with
an increase in serum GGT. WBCs, a major component
of the inflammatory process, are activated by cytokines,
especially interleukin-6 and interleukin-8 [39]. Elevated
GGT could reflect subclinical inflammation, which would
represent the underlying mechanism. Serum GGT level
may be a simple and reliable marker of visceral and hep-
atic fat and, by inference, of hepatic insulin resistance.
These findings suggest that a raised serum GGT level is
an independent risk factor for NIDDM. The elevated
GGT concentration should be added to the list of risk
factors that are common to NIDDM and cardiovascular
disease [13].
Our study had several limitations. First, it is cross
sectional study with no causality effect to report. Also
serum GGT and hsCRP during follow-up was not
included in the analysis. Further, we could not include
several confounding variables in this study, such as fast-
ing insulin concentration. Therefore, fasting insulin con-
centration should be included in future studies.Despite these potential limitations, our findings, which
were obtained from a cross sectional study shows that
serum GGT activity and hsCRP level is significantly in-
creased in patients with type 2 diabetes mellitus com-
pared to healthy control. Both are further increased in
diabetic patients with complications and poor glycemic
control. Also there is a significant positive correlation
between serum GGT activity and hsCRP. Both are also
independently positively correlated with HbA1c, FBS and
PP2BS (short and long term glycemic control). So far,
the underlying pathophysiological mechanisms are not
entirely clear. It seems that insulin resistance, oxidative
stress and chronic low grade systemic inflammation may
be involved. All these finding suggesting a link between
oxidative stress, inflammation and glycemic control in
patient with type 2 diabetes mellitus. Further studies are
needed to investigate the biological mechanisms under-
lying this association.Conclusions
In conclusion, the present study suggests that serum
GGT and hsCRP concentration is significantly increased
in type 2 diabetes mellitus. Both are further increased in
diabetic patients with complications and poor glycemic
control. There is a significant positive correlation be-
tween serum GGT activity and hsCRP. Serum GGT level
and hsCRP concentration was independently and posi-
tively correlated with FBS, PP2BS and HbA1c (markers
of glycemic control). All these finding suggesting a link
between oxidative stress, inflammation and glycemic
control in patient with type 2 diabetes mellitus.
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